|
|
|
European Biopharmaceutical Review
|
| Tom Roche at FM Global examines an approach designed to provide vital company protection for the long term as new risks emerge
All companies take risks – it’s a natural part of succeeding in a competitive business environment. In the pharmaceutical business, as in many others, it’s part of the art of commercial success to calculate a risk – the likelihood, the need to take it, the consequences if the risk becomes the reality – and to plan your business moves accordingly, almost certainly incorporating a healthy dose of risk prevention. That’s the theory, at least, and operating in a globalised economy that has increased the potential for risk at just about every step, it should also be the practice.
For all the organisational sophistication and slick operational performance at the heart of global success, the need for any commercial enterprise – including a major pharmaceutical company – to identify and consider at each stage the possibility of what could go wrong has not diminished. If anything, it has increased, because whether it’s a ‘big bang’ or something far more insidious and systemic, for every benefit globalisation offers there are potential pitfalls which a company ignores at its peril.
REPUTATIONS ON THE LINE
There have been several high profile examples of the reputational risks pharmaceutical companies run in the day-today task of bringing new products to market. Newspapers screaming ‘drug test disaster’ do circulation figures no harm at all, and those unfortunate stories are not easily forgotten. But commercial risks – events and occurrences that can severely damage a corporation if not properly managed – need not be of the headline-making variety.
Recent research in the US and Europe with executives from the world’s leading companies demonstrated that, in a global business, disruption to the supply chain comes second only to competition as a threat to a company’s well-being. In other words, the principle risk to the existence of a global business is largely defined by the way the company itself sets up its own business. An adequate response to this finding is a commercial imperative. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
After graduating from Lancaster University with Bachelor’s and Master’s degrees in Mechanical and
Electronic Engineering, Tom Roche spent his initial engineering career in steel and water industries,
working on industrial automation. Tom joined FM Global in 1993, and has worked within the loss
prevention engineering team, working with local and international clients. In this role, he has helped
clients to implement loss prevention programmes, successfully managed projects to install active fire
protection systems, and has represented the company at numerous client seminars. Tom is currently
the Engineering Manager for the UK Operations within FM Global. In this role, he is responsible for
the team delivering loss prevention engineering services to plant and corporate level clients within
the UK, Ireland, Scandinavia and Italy. |
|
|
|
|
|
 |
News and Press Releases |
 |
AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase
AirBridgeCargo expands its passive pharma solutions in partnership with
SkyCell as it achieves the two-fold volume increase AirBridgeCargo
Airlines (ABC), one of the leaders in transportation of pharmaceutical
products by air, and Zurich-based cold-chain ULD manufacturer SkyCell
have sealed their partnership for the lease of all types of SkyCell
containers to meet the demand for evolving volumes of passive
pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019
YOY and demonstrated a two-fold increase.
More info >> |
|
 |
White Papers |
 |
|
Characterisation of Biopharmaceutical Proteins
Reading Scientific Services Ltd (RSSL)
Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >> |
|
 |
Industry Events |
 |
BioPharm America™ 2019—12th Annual International Partnering Conference
11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA
BioPharm America™ is a unique partnering event that forms the nexus of discovery and
realization. Startup companies, established biotech and entrepreneurs from academia
attend in search of finance, pharma and development partners. The event format highlights
innovation and promotes new business relationships by bringing dealmakers from the life
science ecosystem together to engage and de-risk the enormous task of drug development.
Life science executives from around the world gather to identify, meet and to enter
into strategic relationships facilitated by partneringONE®, the world’s leading
web-based partnering system. BioPharm America is the only event in North America
based on the same reputable formula as EBD Group’s acclaimed European events
BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates
from over 500 companies who participated in 2,300+ scheduled one-to-one meetings.
BioPharm America is now part of Biotech Week Boston, and together they draw a total
of over 4,500 life science leaders, scientists and innovators.
More info >> |
|
|
